MultiCell Technologies, Inc. (MCET) - Financial and Strategic SWOT
Analysis Review
Reference Code: GDPH62104FSA Publication Date: JAN 2013
68 Cumberland Street, Suite 301 Phone +1 401 7620045 Revenue 0.1 (million USD)
Woonsocket, RI Fax +1 401 7620098 Net Profit -1.80 (million USD)
02895 Website www.multicelltech.com Employees 2
MCET [Over The Pharmaceuticals &
United States Exchange Industry
Counter] Healthcare
Company Overview
MultiCell Technologies, Inc. (MultiCell), formerly Exten Industries, Inc., is a clinical stage biopharmaceutical company. It focuses
on the development of novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer
and interventional cardiology, and peripheral vessel applications. The company's product pipeline consists of MCT-125, MCT-
465, MCT-475 and MCT-485. The company also specializes in the development of cell immortalization technologies to generate
cell-based assay systems for the drug discovery.
Key Executives SWOT Analysis
Name Title MultiCell Technologies, Inc., SWOT Analysis
W. Gerald Newmin Chairman Strengths Weaknesses
Edward Sigmond Director
Lack of Product Base
Stephen M. Chang, Ph.D. Director Patented Technology Platform
Revenues
Thomas A. Page Director Drug Candidate Portfolio
Business Shortcomings
Scott Lukeman, Ph.D. Director
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData Opportunities Threats
Share Data Focus on Oncology Uncertain R&D Outcomes
MultiCell Technologies, Inc.
Changing Demographics Tough Credit Market Conditions
Share Price (USD) as on 15-Jan- 0.0
2013
Source: Annual Report, Company Website, Primary and Secondary Research,
EPS (USD) 0.0 GlobalData
Market Cap (million USD) 2
Enterprise Value (million USD) 2
Shares Outstanding (million) 1,244
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
Financial Performance Recent Developments
Apr 16, 2012 MultiCell Technologies Reports Q1 Fiscal 2012
Results
Feb 28, 2012 MultiCell Technologies Reports Fiscal 2011
Results
Jan 03, 2012 MultiCell Technologies Receives Final
Payment Under Qualifying Therapeutic
Discovery Project Program
Source: Annual Report, Company Website, Primary and Secondary Research,
GlobalData
Source: Annual Report, Company Website, Primary and Secondary
Research, GlobalData
MultiCell Technologies, Inc. (MCET) - Financial and Strategic Reference Code: GDPH62104FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
Table of Contents
Table of Contents ............................................................................................................................................................................... 2
List of Tables .................................................................................................................................................................................. 4
List of Figures ................................................................................................................................................................................. 4
Section 1 - About the Company.......................................................................................................................................................... 5
MultiCell Technologies, Inc. - Key Facts............................................................................................................................................. 5
MultiCell Technologies, Inc. - Key Employees.................................................................................................................................... 6
MultiCell Technologies, Inc. - Key Employee Biographies ................................................................................................................. 7
MultiCell Technologies, Inc. - Major Products and Services ............................................................................................................... 8
MultiCell Technologies, Inc. - Pharmaceutical Pipeline Products Data .............................................................................................. 9
MultiCell Technologies, Inc., Pipeline Products by Therapy Area ................................................................................................... 9
MultiCell Technologies, Inc., Pipeline Products by Development Phase ...................................................................................... 10
MultiCell Technologies, Inc. - History ............................................................................................................................................... 12
MultiCell Technologies, Inc. - Company Statement .......................................................................................................................... 14
MultiCell Technologies, Inc. - Locations And Subsidiaries ............................................................................................................... 18
Head Office ................................................................................................................................................................................... 18
Other Locations & Subsidiaries ..................................................................................................................................................... 18
Section 2 – Company Analysis ......................................................................................................................................................... 19
MultiCell Technologies, Inc. - Business Description ......................................................................................................................... 19
MultiCell Technologies, Inc. - Corporate Strategy ............................................................................................................................ 20
MultiCell Technologies, Inc. - SWOT Analysis ................................................................................................................................. 21
SWOT Analysis - Overview........................................................................................................................................................... 21
MultiCell Technologies, Inc. - Strengths........................................................................................................................................ 21
Strength - Patented Technology Platform ................................................................................................................................. 21
Strength - Drug Candidate Portfolio .......................................................................................................................................... 21
Strength - License Agreements ................................................................................................................................................. 21
MultiCell Technologies, Inc. - Weaknesses .................................................................................................................................. 21
Weakness - Lack of Product Base Revenues ........................................................................................................................... 21
Weakness - Business Shortcomings ......................................................................................................................................... 22
MultiCell Technologies, Inc. - Opportunities.................................................................................................................................. 22
Opportunity - Focus on Oncology .............................................................................................................................................. 22
Opportunity - Changing Demographics ..................................................................................................................................... 22
Opportunity - Emerging Markets ............................................................................................................................................... 22
MultiCell Technologies, Inc. - Threats ........................................................................................................................................... 23
Threat - Uncertain R&D Outcomes ........................................................................................................................................... 23
Threat - Tough Credit Market Conditions .................................................................................................................................. 23
Threat - Tightening of the FDA’s Regulatory Oversight ............................................................................................................. 23
MultiCell Technologies, Inc. - Key Competitors ................................................................................................................................ 24
Section 3 – Company Financial Ratios ............................................................................................................................................. 25
Financial Ratios - Capital Market Ratios........................................................................................................................................... 25
Financial Ratios - Annual Ratios ...................................................................................................................................................... 25
Performance Chart ........................................................................................................................................................................... 26
Financial Performance...................................................................................................................................................................... 26
Financial Ratios - Interim Ratios....................................................................................................................................................... 27
Financial Ratios - Ratio Charts ......................................................................................................................................................... 28
Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 29
MultiCell Technologies, Inc. (MCET) - Financial and Strategic Reference Code: GDPH62104FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
MultiCell Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ................................................ 29
MultiCell Technologies, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ................................................ 30
MultiCell Technologies, Inc., Recent Deals Summary ...................................................................................................................... 31
Section 5 – Company’s Recent Developments ................................................................................................................................ 32
MultiCell Technologies, Inc., Recent Developments ..................................................................................................................... 32
Apr 16, 2012: MultiCell Technologies Reports Q1 Fiscal 2012 Results .................................................................................... 32
Feb 28, 2012: MultiCell Technologies Reports Fiscal 2011 Results ......................................................................................... 32
Jan 03, 2012: MultiCell Technologies Receives Final Payment Under Qualifying Therapeutic Discovery Project Program ..... 32
Section 6 – Appendix ............................................................................................................................